Endocyte Company Profile (NASDAQ:ECYT)

About Endocyte (NASDAQ:ECYT)

Endocyte logoEndocyte Inc. (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company's pipeline includes Folate-Tubulysin (EC1456), the Company's second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company's non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:ECYT
  • CUSIP: 29269A10
  • Web: www.endocyte.com
Capitalization:
  • Market Cap: $60.03 million
  • Outstanding Shares: 42,575,000
Average Prices:
  • 50 Day Moving Avg: $1.36
  • 200 Day Moving Avg: $1.89
  • 52 Week Range: $1.17 - $3.49
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.74
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $70,000.00
  • Price / Sales: 857.58
  • Book Value: $2.72 per share
  • Price / Book: 0.52
Profitability:
  • EBIDTA: ($40,600,000.00)
  • Net Margins: -61,437.14%
  • Return on Equity: -32.68%
  • Return on Assets: -31.29%
Debt:
  • Current Ratio: 22.81%
  • Quick Ratio: 22.81%
Misc:
  • Average Volume: 487,703 shs.
  • Beta: 1.62
  • Short Ratio: 2.55
 

Frequently Asked Questions for Endocyte (NASDAQ:ECYT)

What is Endocyte's stock symbol?

Endocyte trades on the NASDAQ under the ticker symbol "ECYT."

How were Endocyte's earnings last quarter?

Endocyte, Inc. (NASDAQ:ECYT) posted its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by $0.03. The company earned $0.01 million during the quarter. Endocyte had a negative return on equity of 32.68% and a negative net margin of 61,437.14%. During the same quarter in the previous year, the business earned ($0.25) earnings per share. View Endocyte's Earnings History.

Where is Endocyte's stock going? Where will Endocyte's stock price be in 2017?

3 brokerages have issued 1 year price objectives for Endocyte's stock. Their forecasts range from $2.00 to $7.00. On average, they expect Endocyte's stock price to reach $4.50 in the next twelve months. View Analyst Ratings for Endocyte.

What are analysts saying about Endocyte stock?

Here are some recent quotes from research analysts about Endocyte stock:

  • 1. According to Zacks Investment Research, "Endocyte reported wider than expected loss in second-quarter 2017. During the quarter, the company stopped enrollment in the phase Ib study evaluating EC1456 for lung cancer as well as stop enrollment of taxane-naive metastatic castration-resistant prostate cancer patients for EC1169. The company now plans to focus on its most promising programs like CAR T-cell small-molecule drug conjugates (SMDC) adaptor platform, and its pipeline candidate EC2629. However, with no approved product in its portfolio at the moment, Endocyte has to depend heavily on its partners for top-line growth. Moreover, shares of the company have underperformed the industry year to date." (8/14/2017)
  • 2. Cowen and Company analysts commented, "Today a late breaking abstract was presented at the AACR conference with pre-." (4/5/2017)

Who are some of Endocyte's key competitors?

Who are Endocyte's key executives?

Endocyte's management team includes the folowing people:

  • John C. Aplin Ph.D., Independent Chairman of the Board
  • Michael A. Sherman, President, Chief Executive Officer, Director
  • Michael T. Andriole, Chief Financial Officer
  • Philip S. Low Ph.D., Chief Science Officer, Director
  • Michael A. Brinkley, Vice President - Quality
  • Christopher P. Leamon Ph.D., Vice President - Research
  • P. David Mozley M.D., Vice President - Imaging
  • Katherine K. Parker, Vice President of Human Resources
  • Beth A. Taylor, Corporate Controller
  • Cooper Lesley Russell, Director

Who owns Endocyte stock?

Endocyte's stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (8.34%), Vanguard Group Inc. (3.13%), Pinnacle Associates Ltd. (1.84%), Goldman Sachs Group Inc. (1.01%), California Public Employees Retirement System (0.61%) and JPMorgan Chase & Co. (0.57%). Company insiders that own Endocyte stock include Christopher P Leamon, Fred A Middleton and Philip S Low. View Institutional Ownership Trends for Endocyte.

Who sold Endocyte stock? Who is selling Endocyte stock?

Endocyte's stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Northern Trust Corp, Vanguard Group Inc., Parametric Portfolio Associates LLC, Ameriprise Financial Inc., Pinnacle Associates Ltd. and Royal Bank of Canada. View Insider Buying and Selling for Endocyte.

Who bought Endocyte stock? Who is buying Endocyte stock?

Endocyte's stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., LMR Partners LLP, Spark Investment Management LLC, FMR LLC and Dimensional Fund Advisors LP. Company insiders that have bought Endocyte stock in the last two years include Fred A Middleton and Philip S Low. View Insider Buying and Selling for Endocyte.

How do I buy Endocyte stock?

Shares of Endocyte can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Endocyte's stock price today?

One share of Endocyte stock can currently be purchased for approximately $1.41.


MarketBeat Community Rating for Endocyte (NASDAQ ECYT)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  182 (Vote Outperform)
Underperform Votes:  123 (Vote Underperform)
Total Votes:  305
MarketBeat's community ratings are surveys of what our community members think about Endocyte and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Endocyte (NASDAQ:ECYT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $4.50 (219.15% upside)

Analysts' Ratings History for Endocyte (NASDAQ:ECYT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/5/2017WedbushDowngradeOutperform -> Neutral$8.00 -> $2.00HighView Rating Details
6/2/2017Cowen and CompanyDowngradeOutperform -> Market PerformLowView Rating Details
11/11/2016Credit Suisse GroupReiterated RatingBuy$7.00N/AView Rating Details
11/4/2015Royal Bank Of CanadaLower Price TargetOutperform$13.00 -> $10.00N/AView Rating Details
(Data available from 9/19/2015 forward)

Earnings

Earnings History for Endocyte (NASDAQ:ECYT)
Earnings by Quarter for Endocyte (NASDAQ:ECYT)
Earnings History by Quarter for Endocyte (NASDAQ ECYT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 2017($0.25)($0.28)$0.01 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.28)($0.27)$0.01 millionViewN/AView Earnings Details
3/10/2017Q4 2016($0.25)($0.26)$0.01 millionViewN/AView Earnings Details
11/9/2016Q316($0.27)($0.21)$0.03 millionViewListenView Earnings Details
8/4/2016Q2($0.26)($0.25)$0.01 millionViewN/AView Earnings Details
5/4/2016Q116($0.25)($0.24)$0.01 millionViewListenView Earnings Details
3/2/2016Q4($0.27)($0.23)$0.01 millionViewListenView Earnings Details
11/3/2015Q315($0.27)($0.24)$0.03 millionViewN/AView Earnings Details
8/4/2015Q215($0.30)($0.25)$0.01 millionViewN/AView Earnings Details
5/7/2015Q115($0.24)($0.26)$0.01 millionViewN/AView Earnings Details
3/2/2015Q414($0.24)($0.19)$2.55 million$12.00 millionViewN/AView Earnings Details
11/5/2014Q314($0.21)($0.14)$5.10 million$3.90 millionViewN/AView Earnings Details
7/29/2014Q214$0.11$0.52$26.62 million$49.17 millionViewN/AView Earnings Details
5/2/2014Q114($0.15)($0.09)$15.07 million$17.30 millionViewN/AView Earnings Details
2/24/2014Q413($0.14)($0.08)$15.90 million$17.30 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.06)($0.11)$14.24 million$14.50 millionViewN/AView Earnings Details
4/15/2013Q413($0.10)$8.50 million$13.60 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Endocyte (NASDAQ:ECYT)
2017 EPS Consensus Estimate: ($1.07)
2018 EPS Consensus Estimate: ($0.82)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.32)($0.32)($0.32)
Q2 20171($0.33)($0.33)($0.33)
Q3 20171($0.23)($0.23)($0.23)
Q4 20171($0.19)($0.19)($0.19)
Q1 20181($0.20)($0.20)($0.20)
Q2 20181($0.20)($0.20)($0.20)
Q3 20181($0.21)($0.21)($0.21)
Q4 20181($0.21)($0.21)($0.21)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Endocyte (NASDAQ:ECYT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Endocyte (NASDAQ:ECYT)
Insider Ownership Percentage: 14.86%
Institutional Ownership Percentage: 28.80%
Insider Trades by Quarter for Endocyte (NASDAQ:ECYT)
Institutional Ownership by Quarter for Endocyte (NASDAQ:ECYT)
Insider Trades by Quarter for Endocyte (NASDAQ:ECYT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/30/2016Christopher P. LeamonVPSell23,244$2.55$59,272.20View SEC Filing  
5/10/2016Philip S LowInsiderBuy11,375$3.52$40,040.00View SEC Filing  
1/19/2016Fred A. MiddletonDirectorBuy10,000$2.79$27,900.00View SEC Filing  
1/15/2016Fred A. MiddletonDirectorBuy20,000$2.80$56,000.00View SEC Filing  
4/9/2014Allen RitterVPSell1,000$21.16$21,160.00View SEC Filing  
3/21/2014Allen RitterVPSell8,000$33.11$264,880.00View SEC Filing  
2/14/2014Philip LowInsiderSell6,000$15.00$90,000.00View SEC Filing  
12/2/2013P Ron EllisCEOSell3,000$12.00$36,000.00View SEC Filing  
9/16/2013Allen RitterVPSell2,000$17.06$34,120.00View SEC Filing  
9/12/2013David MeekInsiderSell10,000$15.50$155,000.00View SEC Filing  
9/3/2013P Ron EllisCEOSell3,000$14.54$43,620.00View SEC Filing  
8/30/2013Allen RitterVPSell6,000$14.36$86,160.00View SEC Filing  
8/6/2013Chandra LovejoyVPSell7,000$17.29$121,030.00View SEC Filing  
8/1/2013P Ron EllisCEOSell3,000$18.12$54,360.00View SEC Filing  
7/15/2013P Ron EllisCEOSell3,000$17.01$51,030.00View SEC Filing  
5/28/2013Ann HanhamDirectorSell9,900$14.10$139,590.00View SEC Filing  
5/22/2013Ann HanhamDirectorSell40,000$14.38$575,200.00View SEC Filing  
5/17/2013Ann HanhamDirectorSell37,200$14.41$536,052.00View SEC Filing  
5/17/2013Binh NguyenVPSell17,300$14.42$249,466.00View SEC Filing  
5/15/2013Ann HanhamDirectorSell40,200$14.69$590,538.00View SEC Filing  
5/14/2013Christopher P LeamonVPSell5,000$14.70$73,500.00View SEC Filing  
2/25/2013Chandra D LovejoyVPSell2,102$9.70$20,389.40View SEC Filing  
12/26/2012Chandra D LovejoyVPSell2,209$9.05$19,991.45View SEC Filing  
11/26/2012Chandra D LovejoyVPSell2,209$8.72$19,262.48View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Endocyte (NASDAQ:ECYT)
Latest Headlines for Endocyte (NASDAQ:ECYT)
Source:
DateHeadline
americanbankingnews.com logoEndocyte, Inc. (ECYT) Expected to Post Earnings of -$0.21 Per Share
www.americanbankingnews.com - September 17 at 4:44 PM
globenewswire.com logoEndocyte Presents Data at the 2017 CAR-TCR Summit Further Demonstrating the Ability to Manage Cytokine Release ... - GlobeNewswire (press release)
globenewswire.com - September 6 at 6:06 PM
finance.yahoo.com logoEndocyte Presents Data at the 2017 CAR-TCR Summit Further Demonstrating the Ability to Manage Cytokine Release Syndrome Related to CAR T-Cell Therapy
finance.yahoo.com - September 6 at 6:06 PM
streetinsider.com logoEndocyte (ECYT) Announces Presentation at ESMO
www.streetinsider.com - September 6 at 5:45 AM
streetinsider.com logoEndocyte (ECYT) Announces Presentation at ESMO - StreetInsider.com
www.streetinsider.com - September 6 at 12:44 AM
finance.yahoo.com logoEndocyte Announces Presentation at the European Society for Medical Oncology (ESMO)
finance.yahoo.com - September 5 at 7:42 PM
finance.yahoo.com logoETFs with exposure to Endocyte, Inc. : August 31, 2017
finance.yahoo.com - August 31 at 11:03 PM
americanbankingnews.com logo Analysts Anticipate Endocyte, Inc. (ECYT) to Announce -$0.21 EPS
www.americanbankingnews.com - August 30 at 4:06 AM
finance.yahoo.com logoEndocyte, Inc. :ECYT-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 7:05 PM
feeds.benzinga.com logoEndocyte Announces Presentations at the 254th American Chemical Society National Meeting & Exposition
feeds.benzinga.com - August 16 at 8:49 AM
americanbankingnews.com logoEndocyte, Inc. (ECYT) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - August 14 at 3:14 PM
americanbankingnews.com logoEndocyte, Inc. (ECYT) Forecasted to Post Q3 2017 Earnings of ($0.23) Per Share
www.americanbankingnews.com - August 14 at 3:18 AM
bizjournals.com logoBiotech Stocks on Investors' Radar -- Dermira, Endocyte, FibroGen, and Global Blood Therapeutics
www.bizjournals.com - August 11 at 11:38 PM
americanbankingnews.com logo Analysts Expect Endocyte, Inc. (NASDAQ:ECYT) to Announce -$0.22 EPS
www.americanbankingnews.com - August 11 at 6:30 PM
americanbankingnews.com logoEndocyte, Inc. (ECYT) Releases Earnings Results, Misses Expectations By $0.03 EPS
www.americanbankingnews.com - August 10 at 3:16 PM
nasdaq.com logoEndocyte (ECYT) Stock Up Despite Wider-than-Expected Q2 Loss - Nasdaq
www.nasdaq.com - August 9 at 6:15 PM
finance.yahoo.com logoEdited Transcript of ECYT earnings conference call or presentation 8-Aug-17 8:30pm GMT
finance.yahoo.com - August 9 at 6:15 PM
finance.yahoo.com logoEndocyte (ECYT) Stock Up Despite Wider-than-Expected Q2 Loss
finance.yahoo.com - August 9 at 6:15 PM
finance.yahoo.com logoEndocyte reports 2Q loss
finance.yahoo.com - August 9 at 6:15 PM
globenewswire.com logoEndocyte Reports Second Quarter Financial Results and Provides Clinical and Pipeline Update - GlobeNewswire (press release)
globenewswire.com - August 8 at 5:52 PM
finance.yahoo.com logoEndocyte Reports Second Quarter Financial Results and Provides Clinical and Pipeline Update
finance.yahoo.com - August 8 at 5:52 PM
seekingalpha.com logoEndocyte misses by $0.03
seekingalpha.com - August 8 at 4:51 PM
finance.yahoo.com logoShire (SHPG) Beats on Q2 Earnings & Sales, Updates '17 View
finance.yahoo.com - August 4 at 6:25 PM
finance.yahoo.com logoSpectrum (SPPI) Q2 Loss Narrower than Expected, Sales Beat
finance.yahoo.com - August 4 at 6:25 PM
globenewswire.com logoEndocyte Announces Second Quarter 2017 Earnings Conference Call - GlobeNewswire (press release)
globenewswire.com - August 2 at 4:47 AM
globenewswire.com logoEndocyte Announces Second Quarter 2017 Earnings Conference ... - GlobeNewswire (press release)
www.globenewswire.com - August 1 at 11:46 PM
finance.yahoo.com logoEndocyte Announces Second Quarter 2017 Earnings Conference Call
finance.yahoo.com - August 1 at 6:45 PM
nasdaq.com logoWhat's in Store for Endocyte (ECYT) this Earnings Season?
www.nasdaq.com - July 26 at 6:43 PM
finance.yahoo.com logoWhat's in Store for Endocyte (ECYT) this Earnings Season?
finance.yahoo.com - July 26 at 6:43 PM
americanbankingnews.com logo-$0.25 Earnings Per Share Expected for Endocyte, Inc. (ECYT) This Quarter
www.americanbankingnews.com - July 24 at 12:36 PM
americanbankingnews.com logoEndocyte, Inc. (NASDAQ:ECYT) Short Interest Update
www.americanbankingnews.com - July 17 at 7:18 AM
finance.yahoo.com logoEndocyte (ECYT) to Focus on Promising CAR-T Cell Platform
finance.yahoo.com - July 13 at 7:24 PM
americanbankingnews.com logo Analysts Anticipate Endocyte, Inc. (ECYT) to Post -$0.25 EPS
www.americanbankingnews.com - June 28 at 8:28 AM
finance.yahoo.com logoETFs with exposure to Endocyte, Inc. : June 20, 2017
finance.yahoo.com - June 20 at 5:34 PM
finance.yahoo.com logoWhy Is Endocyte (ECYT) Down 37.9% Since the Last Earnings Report?
finance.yahoo.com - June 14 at 5:54 PM
americanbankingnews.com logoEndocyte, Inc. (ECYT) Upgraded at Zacks Investment Research
www.americanbankingnews.com - June 8 at 10:58 AM
americanbankingnews.com logoWedbush Comments on Endocyte, Inc.'s Q3 2017 Earnings (ECYT)
www.americanbankingnews.com - June 7 at 8:28 AM
finance.yahoo.com logoETFs with exposure to Endocyte, Inc. : June 5, 2017
finance.yahoo.com - June 5 at 4:58 PM
rttnews.com logoAMGN Finds New Use For Old Drug, NLNK Disappointed, ECYT Cuts Workforce
www.rttnews.com - June 5 at 11:40 AM
americanbankingnews.com logoEndocyte, Inc. (ECYT) Cut to "Neutral" at Wedbush
www.americanbankingnews.com - June 5 at 9:15 AM
globenewswire.com logoEndocyte Announces Clinical Updates for EC1456 and EC1169 - GlobeNewswire (press release)
globenewswire.com - June 4 at 4:58 PM
americanbankingnews.com logoValuEngine Downgrades Endocyte, Inc. (ECYT) to Strong Sell
www.americanbankingnews.com - June 3 at 4:28 PM
americanbankingnews.com logoEndocyte, Inc. (ECYT) Stock Rating Lowered by Cowen and Company
www.americanbankingnews.com - June 2 at 5:42 PM
finance.yahoo.com logoEndocyte Announces Clinical Updates for EC1456 and EC1169
finance.yahoo.com - June 2 at 4:21 PM
finance.yahoo.com logoEndocyte stock plummets 30% on news of major workforce reduction; clinical trial changes
finance.yahoo.com - June 2 at 4:21 PM
finance.yahoo.com logoEndocyte, Inc. :ECYT-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 2 at 4:21 PM
americanbankingnews.com logo Brokerages Expect Endocyte, Inc. (ECYT) to Post -$0.29 Earnings Per Share
www.americanbankingnews.com - June 2 at 7:34 AM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Endocyte and CytRx
finance.yahoo.com - May 31 at 9:45 AM
finance.yahoo.com logoBlog Coverage: Endocyte to Present Posters on its Lead Clinical Stage Assets at the ASCO Annual Meeting
finance.yahoo.com - May 31 at 9:45 AM
streetinsider.com logoEndocyte (ECYT) to Report Updated Data on EC1456 and EC1169 at the 2017 American Society of Clinical Oncology ... - StreetInsider.com
www.streetinsider.com - May 27 at 5:16 PM

Social

Chart

Endocyte (ECYT) Chart for Tuesday, September, 19, 2017

This page was last updated on 9/19/2017 by MarketBeat.com Staff